Healthcare Industry News: schizophrenia
News Release - November 28, 2006
Organon and Pfizer Discontinue Their Collaboration on Asenapine
NEW YORK and ARNHEM, Netherlands, Nov. 28 (HSMN NewsFeed) -- Organon and Pfizer today announced that they have agreed to discontinue their collaboration in the further development of asenapine, a new drug candidate for the treatment of schizophrenia and acute mania associated with Bipolar I Disorder.Pfizer's decision to discontinue its participation in the asenapine development program is an outcome of a commercial analysis of the compound as a part of its overall portfolio. Pfizer will return all product rights, intellectual property and data to Organon and make orderly transitions during 2007.
Organon will continue to develop asenapine.
Source: Pfizer
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!